Literature DB >> 33918618

Analysis of Intra-Tumoral Macrophages and T Cells in Non-Small Cell Lung Cancer (NSCLC) Indicates a Role for Immune Checkpoint and CD200-CD200R Interactions.

Anders Tøndell1,2, Yashwanth Subbannayya2,3, Sissel Gyrid Freim Wahl2,4, Arnar Flatberg2,5, Sveinung Sørhaug1, Magne Børset2,6, Markus Haug2,3,7.   

Abstract

Non-small cell lung carcinoma (NSCLC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related deaths. Immunotherapy with immune checkpoint inhibitors shows beneficial responses, but only in a proportion of patients. To improve immunotherapy in NSCLC, we need to map the immune checkpoints that contribute immunosuppression in NSCLC-associated immune cells and to identify novel pathways that regulate immunosuppression. Here, we investigated the gene expression profiles of intra-tumoral immune cells isolated from NSCLC patients and compared them to the expression profiles of their counterparts in adjacent healthy tissue. Transcriptome analysis was performed on macrophages, CD4+ and CD8+ T cells. The data was subjected to Gene Ontology (GO) term enrichment and weighted correlation network analysis in order to identify mediators of immunosuppression in the tumor microenvironment in NSCLC. Immune cells from NSCLC revealed a consistent differential expression of genes involved in interactions between myeloid cells and lymphocytes. We further identified several immunosuppressive molecules and pathways that may be activated in tumor-associated macrophages in NSCLC. Importantly, we report novel data on immune cell expression of the newly described CD200/CD200R1 pathway, and the leukocyte immunoglobulin-like receptors (LILRs), which may represent novel innate immune checkpoints, dampening the anti-tumor T cell immune response in NSCLC. Our study substantiates the importance of tumor-associated macrophages as a mediator of immunosuppression and a promising target for immunotherapy.

Entities:  

Keywords:  immunosuppression; non-small cell lung cancer; tumor microenvironment; tumor-associated macrophages

Year:  2021        PMID: 33918618     DOI: 10.3390/cancers13081788

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  2 in total

1.  Accepting Immunotherapy After Multiline Treatment Failure: An Exploration of the Anxiety and Depression in Patients with Advanced Cancer Experience.

Authors:  Qingqing Xie; Caixia Sun; Zhenghua Fei; Xujing Yang
Journal:  Patient Prefer Adherence       Date:  2022-01-04       Impact factor: 2.711

2.  The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis.

Authors:  Yongsheng Zhang; Yunlong Wang; Jichuang Wang; Kaixiang Zhang
Journal:  Front Genet       Date:  2022-06-21       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.